ArticleBMC ophthalmology2025
Lipidomic analysis of vitreous humor derived from patients with proliferative diabetic retinopathy.
Article in BMC ophthalmology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Understanding the Molecular Basis of Pathological Retinal Angiogenesis: Roles of Lipids, Non-Coding RNAs, and Cellular Crosstalk.Investigative ophthalmology & visual science · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
purposeTo compare the lipid profiles of vitreous humor (VH) obtained from patients with proliferative diabetic retinopathy (PDR) and healthy controls and to determine possible metabolic pathways associated with PDR.
methodsVH samples from both PDR patients (PDR group) and healthy subjects (Control group) were harvested for lipid analysis using high-throughput liquid chromatography tandem mass spectrometry (LC-MS/MS). The differential expressions of lipids between the control and PDR groups were determined by both univariate and multivariate methods. The sensitivity and specificity of the differentially expressed lipids as the candidate biomarkers for DR were determined through the area under receiver operating characteristic (ROC) analysis. MetaboAnalyst 5.0 was used for metabolic pathway analysis.
resultsLipids were abundant in the VH samples, and LC-MS/MS analysis identified 35 lipid classes, 849 lipid species from both groups. There were much higher total lipid levels in the VH derived from PDR patients than that in the controls and the levels of cholesteryl Ester (ChE), phosphatidylserine (PS), phosphatidylcholine (PC), phosphatidylinositol (PI), and sphingomyelin (SM) obviously increased in the PDR patients as compared with the controls (all p < 0.01). Of these lipid species, a total of 256 lipids (245 upregulated and 11 downregulated) were determined by combining univariate and multivariate statistical analyses. ROC analysis showed the selected differentially expressed lipids had an area under ROC greater than 0.8, exhibiting good diagnostic value in distinguishing PDR patients from the controls. Pathway analysis showed that these differentially expressed lipids were mainly enriched in sphingolipid and purine metabolic pathways.
conclusionDifferentially expressed lipids in the VH of PDR patients were shown as ideal candidate metabolic biomarkers for clinical diagnosis and prognosis of DR, shedding new light on the metabolic mechanism of DR.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.